On July 15, 2026 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") and St Vincent’s Hospital reported that the first patients have been dosed with TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) in the OPTIMAL-e trial, led by Professor Louise Emmett for patients with metastatic hormone-sensitive prostate cancer (mHSPC) at St Vincent’s Hospital in Sydney, Australia.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
OPTIMAL-e is a single-arm, open-label trial, evaluating adaptive-dosed TLX597-Tx in combination with androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI) in men with mHSPC. The study will evaluate the impact of TLX597-Tx on PSA4 response rate in an earlier treatment setting, assessing its potential to improve both the depth and durability of PSA response, while further evaluating the safety of dose intensification.
TLX597-Tx is a highly-targeted next generation small molecule RLT5 designed to improve efficacy and quality of life in earlier-stage metastatic prostate cancer. It has demonstrated a favorable biodistribution and dosimetry profile in prior studies including OPTIMAL-PSMA6, suggesting low exposure to salivary glands and the kidneys, the healthy organs of concern with PSMA RLT, and high uptake in PSMA-expressing tumors.
Louise Emmett, MD, Director of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, and Lead Investigator of the OPTIMAL-e study, said, "I am excited to lead the OPTIMAL-e trial, which is evaluating an adaptive treatment approach designed to tailor therapy to each patient’s response. By using PSMA-PET7 imaging and PSA measurements to monitor disease burden, treatment can be continued when the PSMA target persists, and paused when there is a significant reduction in tumor burden. This individualized strategy aims to maintain disease control while minimizing unnecessary treatment exposure, with the potential to keep patients in a low-volume disease state for longer and support quality of life. The findings from OPTIMAL-e may help shape future treatment strategies and advance precision medicine for men living with prostate cancer."
David N. Cade, MD, Group Chief Medical Officer, Telix, said, "The initiation of OPTIMAL-e marks an important evolution of PSMA-targeted radioligand therapy for earlier metastatic prostate cancer, where maintaining quality of life is paramount. While the currently approved radioligand therapy has demonstrated a modest improvement in overall survival in advanced-stage disease, we believe earlier intervention may offer the potential to further improve outcomes and prolong quality of life for patients."
TLX597-Tx has not received marketing authorization in any jurisdiction.
About OPTIMAL-e
OPTIMAL-e is a Phase 2, non-randomized pilot study evaluating adaptive-dosed TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) in combination with ADT and an ARPI in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Adaptive dosing of 177-Lu-PSMA is the concept of only treating if the PSMA target is persistent, while pausing treatment if there is a marked reduction in the tumor target, with re-treatment at first confirmed PSA rise (once the target has returned). The study is investigating whether intensified, response-adapted PSMA-targeted radioligand therapy can deepen responses, improve disease control and enable treatment pauses for selected patients based on PSMA-PET imaging and PSA outcomes.
TLX597-Tx is being developed alongside TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan), Telix’s lead antibody-based prostate cancer therapy candidate, currently the subject of the Phase 3 ProstACT Global8 trial in mCRPC9, which is actively dosing patients in jurisdictions with regulatory approval. TLX591-Tx and TLX597-Tx exhibit complementary modes-of-action, suggesting the potential for distinct applications in mCRPC and mHSPC settings as part of Telix’s portfolio approach to treating prostate cancer.
(Press release, Telix Pharmaceuticals, JUL 15, 2026, View Source [SID1234669249])